

Developing Lead compound of AURKA Degraderefor a potential anti-cancer therapy

UPPthera, Inc.



ONCOLOGY	Lead
Product Type	Small molecule (Target Protein Degradere)
Indication	Small Cell Lung Cancer, Neuroblastoma etc.
Target	AURKA (Aurora kinase A)
MoA(Mechanism of Action)	TPD (AURKA Degradation by Ubiquitin-Proteasome Pathway)
Competitiveness	<ul style="list-style-type: none"> • AURKA is a mitotic kinase to regulate cell cycle particularly in G2/M phase. This protein has non-catalytic as well as catalytic function • Degradere induces a proximity between target protein and E3 ligase protein. Degradere-induced AURKA degradation is able to destroy all of it's catalytic and non-catalytic function, it induces cell cycle arrest and apoptosis • Anti-cancer effects in various cancer cell lines(SCLC, Neuroblastoma), with no observed toxicity in normal cells • Superior G2/M arrest-inducing ability compared to the AURKA inhibitor • Identified the potential for oral administration in Mouse PK studies
Development Stage	Lead
Route of Administration	P.O.